Melanie B. Thomas, MD

Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Though surgery is the only curative option for patients with extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinomas (GBCA), there is still a high risk of the cancer returning.

There remains a need for an option for these patients after surgery.

This trial established the feasibility of adjuvant treatment in EHCC and GBCA.

Videos

Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Adjuvant Capecitabine/Gemcitabine for EHCC and GBCA

Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody

PF-03446962 in hepatocellular carcinoma (HCC)

PF-03446962 is a fully human IgG2 monoclonal antibody against ALK-1.

Higher tumor c-MET and serum BMP-9, and low serum TGF-&beta; and VEGFR3 were observed in patients with disease control at 12 weeks compared with patients with progressive disease.

This agent was mostly well tolerated  rashes were observed in some patients.

PF-03446962 will be looked at next compared with placebo in the second-line for HCC.

View more from the 2014 ASCO Annual Meeting

Melanie B. Thomas, MD, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).

Melanie B. Thomas, MD | Authors

Articles

Adjuvant Capecitabine/Gemcitabine for EHCC and GBCA

The Monoclonal Antibody PF-03446962 for HCC